title: Bevacizumab for the treatment of nonsquamous non-small-cell lung cancer in Portugal: a retrospective, multicenter study.
abstract: BACKGROUND
  Lung cancer is the leading cause of cancer-related mortality. In patients with nonsquamous non-small-cell lung cancer (NSCLC) stage IIIB/IV treatment with chemotherapy plus bevacizumab led to significant improvements in progression-free and median overall survival (OS).
  
  
  OBJECTIVE
  To report the experience of five Portuguese centers in treating patients with nonsquamous NSCLC in stage IIIB or IV with bevacizumab and chemotherapy regarding survival and toxicity outcomes.
  
  
  METHODS
  This was a retrospective, multicenter study on patients with nonsquamous stage IIIB/IV NSCLC treated with bevacizumab and chemotherapy from November 2007 to August 2010 through special use permits. We reviewed the medical records, registry of demographic characteristics, treatments provided, treatment responses, adverse events, and dates of death. Statistical analysis was performed with SPSS statistics software. Median OS and event-free survival (EFS) were calculated using the Kaplan-Meier method.
  
  
  RESULTS
  From an eligible population of 41 patients, 37 participants were registered. Study participants were predominantly male (78.4%) with a median age of 53 years (29-75 years). In total, 83.8% patients had stage IV disease (TNM, 6th Ed.). The OS was 21.5 months (95% confidence interval [CI]: 12.6-30.5] and median EFS was 9.4 months (95% CI9: 7.1-11.7). Hematologic toxicity grade 3/4 occurred in 35.1% of patients, and nonhematologic toxicity in 24.3% patients. One fatal thromboembolic event was recorded (2.7%).
  
  
  CONCLUSIONS
  The results of chemotherapy plus bevacizumab treatment for nonsquamous NSCLC obtained from the daily clinical practice of the centers involved in this study were similar to those of published clinical trials. Collaboration between the different Portuguese centers is crucial for this kind of study.
authors.affiliation: Medical Oncology Resident, Department of Medical Oncology, Portuguese Institute of Oncology, Oporto Center, Oporto, Portugal.
authors.forename: Fernanda
authors.initials: F
authors.lastname: Estevinho
authors.forename: Marta
authors.initials: M
authors.lastname: Soares
authors.forename: Isabel
authors.initials: I
authors.lastname: Azevedo
authors.forename: Henrique
authors.initials: H
authors.lastname: Queiroga
authors.forename: Bárbara
authors.initials: B
authors.lastname: Parente
authors.forename: Ulisses
authors.initials: U
authors.lastname: Brito
authors.forename: Encarnação
authors.initials: E
authors.lastname: Teixeira
authors.forename: Renato
authors.initials: R
authors.lastname: Sotto-Mayor
authors.forename: António
authors.initials: A
authors.lastname: Araújo